A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic IB-ND VLPs-COVID-19 vaccine: A novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) inhibit SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 11.01 pm

A vaccine against SARS-COV-2: Repurposing the Influenza A (H1N1)/Flu vaccine into a Prophylactic Flu-COVID-19 vaccine: Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 5/April/2020, 3.14 pm
April 5, 2020
Hyperthermia-based Prophylatic therapy against SARS-COV-2/COVID-19: Hyperthermia (40C to 43C) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 15/April/2020, 12.27 am
April 14, 2020
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic IB-ND VLPs-COVID-19 vaccine: A novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) inhibit SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 10.59 pm


What is known?

Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that a novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) vaccine-based therapy, with detailed mechanistic insights, for COVID-19 and other infectious diseases. Chimeric IB-ND VLPs vaccine, by increasing the expression of its target genes, it could increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it could: (1) inhibit the replication of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing ” Chimeric IB-ND VLPs vaccine, either alone or in combination with other drugs/compounds, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV (Adenovirus), Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

This image has an empty alt attribute; its file name is IB-ND-Virus-Like-Particles-VLPs-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production1--770x578.jpg

Figure 1. Mechanistic insight into how IB-ND VLPs vaccine prevent/protect against SARS-COV-2. Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2 &  SARS-COV-1 through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, and others.

This image has an empty alt attribute; its file name is IB-ND-Virus-Like-Particles-VLPs-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production2--770x578.jpg

Figure 2 Mechanistic insight into how IB-ND Virus-Like Particles (VLPs)  vaccine functions as a broad spectrum anti-infective agent. Influenza A (H1N1)/Flu vaccine inhibits SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, Foot and Mouth disease virus, ADV, and SFV viruses production through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2 and others.

This image has an empty alt attribute; its file name is IB-ND-Virus-Like-Particles-VLPs-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production4-770x578.jpg

Figure 3.  IB-ND Virus-like particles (VLPs) vaccine can prevent/treat/protect against SARS-COV-2.

This image has an empty alt attribute; its file name is IB-ND-Virus-Like-Particles-VLPs-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production3--770x578.jpg

Figure 4.  IB-ND Virus-like particles (VLPs) vaccine can function as a broad-spectrum anti-infective agent.

This image has an empty alt attribute; its file name is IB-ND-Virus-Like-Particles-VLPs-Vaccine-aids-in-attenuation-of-SARS-coronavirus1-and-2-production5-770x578.jpg

Figure 5.  Repurposing the IB-ND Virus-like particles (VLPs) vaccine into a SARS-COV-2 (Flu-SARS-COV vaccine) vaccine. GBMD (genomediscovery.org) is looking for Scientists/Professor/Medical faculties who would be interested in collaborating with us.


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How IB-ND Virus-like particles (VLPs) vaccine   increases the expression of antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org or admin@genomediscovery.org


References: 

CitationBoominathan L, A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic Flu-COVID-19 vaccine: IB-ND Virus-like particles (VLPs) vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 11.01 pm, and others

Courtesy: When you cite drop us a line at info@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.